
Oncology NEWS International
- Oncology NEWS International Vol 4 No 12
- Volume 4
- Issue 12
UT - Houston to Test Alternative Cancer Agents
HOUSTON--The University of Texas-Houston Health Science Center has been selected by the National Institutes of Health to be home to one of eight specialty centers that will conduct research into the effectiveness of alternative medicines used in cancer treatment.
HOUSTON--The University of Texas-Houston Health Science Centerhas been selected by the National Institutes of Health to be hometo one of eight specialty centers that will conduct research intothe effectiveness of alternative medicines used in cancer treatment.
UT-Houston is expected to receive $733,350 over a 3-year periodfrom the NIH Office of Alternative Medicine. The research willbe conducted in the Center for Health Promotion Research and Developmentat the School of Public Health.
Guy S. Parcel, PhD, principal investigator and director of theCenter, said that the primary aim of the research will be to evaluatethe effectiveness of biopharmacologic and herbal therapies forcancer prevention and treatment. Biopharmacologic therapies mayinclude biochemical agents, vaccines, blood products, or syntheticchemicals, while herbal therapies are those derived from plantssuch as the mayapple, periwinkle, and Pacific yew tree.
"Despite the widespread use of alternative therapies, manyhave not undergone rigorous scientific testing for their effectivenessand safety," Dr. Parcel said. The first task will be an evaluationof the scientific studies that do exist so that a research agendacan be set, he said. The Center hopes to begin funding projectsin the second year of the grant.
Articles in this issue
almost 30 years ago
Confusion Abounds Over Breast Cancer Risk Factorsalmost 30 years ago
Mislocation of BRCA1 Gene Linked to Nonfamilial Breast Canceralmost 30 years ago
Regular Aspirin Use May Lower Breast Cancer Riskalmost 30 years ago
Study Probes How Aspirin Decreases Prostaglandin Levelsalmost 30 years ago
Scholarships Offered For Palliative Carealmost 30 years ago
Rhône-Poulenc Rorer Acquires Applied Immune Sciencesalmost 30 years ago
National Breast Cancer Month Spotlights Awareness Effortsalmost 30 years ago
Long-term Aspirin Use Reduces Colon Cancer Risk, Study Showsalmost 30 years ago
Panel Recommends FDA Approval of First Protease Inhibitoralmost 30 years ago
FDA Improves Drug Approval TimesNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















































































